FONDATION-IPSEN
23.5.2017 07:32:05 CEST | Business Wire | Press release
The Fondation IPSEN (1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. The Fondation IPSEN Endocrine Regulations Prize (2) will be presented today at the ECE (European Congress of Endocrinology) in Lisbon. An international jury (3) chaired by Professor Iain Robinson (National Institute for Medical Research, London, UK ), awarded the prize to Bruce Mc Ewen for his pioneering work on glucocorticoids, stress and neuronal degeneration.
The Fondation IPSEN(1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians from different backgrounds. Created in 2002, the Endocrine Regulations Prize(2) of the Fondation IPSEN awards renowned specialists who made breakthrough discoveries or significant progress in the field. Pr Bruce McEwen has been awarded by an international jury(3) for his pioneering work on glucocorticoids, stress and neuronal degeneration. The prize will be presented at the ECE (European Congress of Endocrinology), followed by a lecture given by Bruce McEwen.
During his talk, Bruce McEwen will discuss about the role of the steroid
hormones that are produced in the brain which mediate every aspect of
brain function. This has broadened the definition of
‘neuroendocrinology’ to include the reciprocal communication between the
brain and the body via hormonal and neural pathways.
The brain is
the central organ of stress and adaptation to stress because it
perceives and determines what is threatening, as well as the behavioural
and physiological responses to the stressor. The adult and developing
brain possess remarkable structural and functional plasticity in
response to stress, including neuronal replacement, dendritic
remodelling, and synapse turnover. Stress causes an imbalance of neural
circuitry subserving cognition, decision-making, anxiety and mood. This
imbalance, in turn, affects systemic physiology via neuroendocrine,
autonomic, immune and metabolic mediators. In the short term, as for
increased fearful vigilance and anxiety in a threatening environment,
these changes may be adaptive. But, if the danger passes and the
behavioural state persists along with the changes in neural circuitry,
such maladaptation may need intervention with a combination of
pharmacological and behavioural therapies, as is the case for chronic
anxiety and depression. Moreover, adverse early-life experience, produce
lasting effects on brain and body over the life-course via epigenetic
mechanisms. While prevention is most important, the plasticity of the
brain gives hope for therapies that take into consideration brain–body
interactions.
Biography
Bruce S. McEwen obtained his Ph.D. in Cell
Biology in 1964 from The Rockefeller University.
He is a member
of the US National Academy of Sciences, the National Academy of
Medicine, and the American Academy of Arts and Sciences. He served as
President of the Society for Neuroscience in 1997-98. As a
neuroscientist and neuroendocrinologist, McEwen studies
environmentally-regulated, variable gene expression in brain, mediated
by circulating steroid hormones and endogenous neurotransmitters in
relation to brain sexual differentiation and the actions of sex and
stress hormones on the adult brain. His laboratory discovered adrenal
steroid receptors in the hippocampus in 1968 that was the gateway for
discovering effects of circulating hormones on cognitive function, mood
regulation and other CNS functions. His laboratory combines molecular,
anatomical, pharmacological, physiological and behavioral methodologies
and relates their findings to human clinical information. His current
research focuses on stress effects on amygdala and prefrontal cortex, as
well as hippocampus, and his laboratory also investigates sex hormone
effects and sex differences in these brain regions involved in cognitive
function and mood regulation. He served on the MacArthur Foundation
Research Network on Socioeconomic Status and Health, in which he has
helped to reformulate concepts and measurements related to stress and
stress hormones in the context of human societies. This led to the
concept of “allostatic load and overload” that describes the wear and
tear on the body and brain from chronic stress and related life style
behaviors that lead to dysregulation of physiological stress pathways
that are normally protective.
He is also a member of the National
Council on the Developing Child which focuses on biological embedding of
early life experiences and promoting healthy brain development.
He
is the co-author of a book with science writer, Elizabeth Lasley, for a
lay audience called “The End of Stress as We Know It”, published in
2002, and “The Hostage Brain” with science writer, the late Harold M.
Schmeck, Jr., published in 1994.
(1) The Fondation IPSEN
Established in 1983 under the
aegis of the Fondation de France, the ambition of the Fondation IPSEN is
to initiate a reflection about the major scientific issues of the
forthcoming years. The long-standing mission of the Fondation IPSEN is
to contribute to the development and dissemination of scientific
knowledge by fostering interaction between scientists and clinicians. It
has developed an important international network of scientific experts
who meet regularly at meetings known as Colloques Médecine et
Recherche
, dedicated to three main topics: neurosciences,
endocrinology and cancer science. Moreover the Fondation IPSEN has
started several series of meetings in partnership with the Salk
Institute, the Karolinska Institute as well as with the journals Cell
and Science
. The Fondation IPSEN produced several hundred
publications and more than 250 scientists have been awarded prizes and
grants.
www.fondation-ipsen.org
(2) The Endocrine Regulations Prize laureates
Created
in 2002, this Prize of
the Fondation Ipsen
has been
awarded to following the renowned specialists: Wylie VALE
(2002), Robert
LEFKOWITZ
(2003), Pierre CHAMBON
(2004), Thomas HÖKFELT
(2005), Roger CONE
(2006), William CROWLEY
(2007), Ronald
EVANS
(2008), Gilbert VASSART
(2009), Shlomo MELMED
(2010), Paolo SASSONE-CORSI
(2011), Jeffrey M. FRIEDMAN
(2012), Bert O’MALLEY
(2013), Maria I. NEW
(2014), C.
Ronald Kahn
(2015) and John W. FUNDER
(2016).
(3) Members of the jury
Iain ROBINSON
(National
Institute for Medical Research, London, UK)
, President
Xavier
BERTAGNA
(Hôpital Cochin, Paris, France)
Felipe
CASANUEVA
(University of Santiago de Compostela, Santiago de
Compostela, Spain)
Michael CONN
(Texas Tech
University Health Sciences Center, El Paso, USA)
Ezio GHIGO
(Ospedale Molinette, Turin, Italy)
Ilpo HUHTANIEMI
(Imperial
College Faculty of Medicine, London, UK)
Gérard KARSENTY
(Columbia
University Medical Center, New York, USA)
Paul KELLY
(Faculté
de Médecine Necker Enfants Malades, Paris, France)
Stafford
LIGHTMAN
(University of Bristol, Bristol, UK)
Günter
STALLA
(Max Planck Institute of Psychiatry, München, Germany
Phyllis
WISE
(University of Illinois, Urbana, USA).
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005878/en/
Contact:
Fondation IPSEN
Yannick TANGUY, Tel. : +33 (0)1 58 33 50 00
E-mail
: fondation@ipsen.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Announces Results of the Annual General Meeting2.4.2026 16:49:00 CEST | Press release
SES (the “Company”) held the Annual General Meeting (“AGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions, including the Company’s 2025 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total dividend amount comprises the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share), which has already been paid to shareholders on October 16, 2025. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on April 16, 2026. “I would like to sincerely thank our shareholders for their active engagement, visionary support and continued confidence in SES’ strategy,” said Adel Al-Saleh, CEO of SES. “The outcomes of today’s AGM underscore our shared commitment to a bold multi-orbit approach, with Medium Earth Orbit as the strategic backbone of a dynamically evolving global interco
Andersen Consulting styrker sine kompetencer med tilføjelsen af Lukkap2.4.2026 16:31:00 CEST | Pressemeddelelse
Andersen Consulting tilføjer samarbejdspartneren Lukkap, et konsulenthus med fokus på oplevelsesdrevne kompetencer, der er tilpasset kundernes skiftende behov inden for transformation af medarbejdere, kunder og det digitale område. Lukkap, der blev stiftet i 2009 og har hovedsæde i Spanien, leverer integrerede løsninger, der hjælper organisationer med at transformere, hvordan de betjener kunder, engagerer medarbejdere og frigør værdi gennem adfærdsindsigt og dataanalyse. Virksomhedens tværfaglige tilgang spænder over nytænkning af kunderejsen, effektive programmer for medarbejderoplevelser, talent- og ledelsesudvikling, prædiktiv analyse samt omfattende outplacement- og transitionsydelser. Lukkap arbejder på tværs af sektorer — herunder sundhedsvæsen, medicinalindustri, forbrugsgoder, detailhandel, finans og bankvæsen — for at opbygge menneskecentrerede strategier, der skaber målbare forretningsresultater. "Ved at kombinere vores erfaringsdrevne metode med Andersen Consultings globale
Forrester: Three Years Into GenAI, Enterprises Are Still Chasing Its True Transformative Value2.4.2026 16:00:00 CEST | Press release
Low AI fluency, uneven adoption, and marginal productivity gains are limiting enterprise-scale impact According to Forrester’s (Nasdaq: FORR) latest report, Accelerate Your AI Voyage, most enterprises are struggling to turn growing AI adoption and investment into measurable business impact. One of the key factors holding businesses back is low artificial intelligence quotient (AIQ) — Forrester’s measure of AI aptitude — with many employees lacking a clear understanding of how to use AI. Other barriers include an overemphasis on productivity-focused use cases, difficulty measuring impact, and siloed adoption within individual functions. While these challenges can leave firms frozen in doubt or indecision, the wait-and-see approach to AI adoption is no longer viable. To unlock AI’s full potential, organizations need to focus on four key areas: Define the business outcomes and success metrics for what they want AI to achieve; identify specific use cases for AI deployment aligned to those
The LYCRA Company Announces Strategic Partnership on Renewable LYCRA® Fiber2.4.2026 15:00:00 CEST | Press release
Agreement with Texhong Advances Sustainable Fiber Applications The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the apparel and personal care industries, today announced the signing of a strategic partnership agreement with Texhong International Group Limited (“Texhong”), one of the world’s largest suppliers of core-spun cotton textiles. Under the agreement, Texhong will exclusively partner with The LYCRA Company to bring Renewable LYCRA® fiber made with 30 percent plant-based content* to China’s core-spun yarn sector. This collaboration aims to accelerate the adoption of bio-derived spandex across the global apparel and textile industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402505834/en/ The LYCRA Company announced a strategic partnership with Texhong International Group for renewable LYCRA® fiber. Pictured at the signing ceremony held in Shanghai (left to right): Jason Wang,
Brightfin Unifies Brand Following Proven Optics Merger, Delivering a New Standard for Technology Cost Optimization2.4.2026 15:00:00 CEST | Press release
New identity reflects expanded vision to help CIOs “See Clearly. Spend Better.” Brightfin today announced that, following its merger with Proven Optics, the combined company will operate under a single brand: Brightfin. The unified company brings together deep expertise in Technology Expense Management (TEM) and IT Financial Management (ITFM) to help organizations better understand, manage, and reduce total technology spend. Technology spending will exceed $6 Trillion this year, and for most organizations, it remains one of the least understood. CIOs can tell you what they’re spending. Far fewer can tell you whether it’s working. “Over the past several months, we’ve brought these two businesses together around a shared purpose: help enterprise businesses better understand and optimize their technology spend,” said Joel Martins, CEO of Brightfin. “What we are seeing now is a shift. Visibility alone isn’t enough. Teams need to be able to act, tied to real financial outcomes. See Clearly.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
